Total Payments
$405,192
2024 Payments
$151,570
Companies
47
Transactions
865
Medicare Patients
1,075
Medicare Billing
$234,271
Payment Breakdown by Category
Other$281,709 (69.5%)
Consulting$66,705 (16.5%)
Food & Beverage$30,465 (7.5%)
Travel$21,155 (5.2%)
Research$4,672 (1.2%)
Education$486.69 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $253,702 | 85 | 62.6% |
| Consulting Fee | $66,705 | 26 | 16.5% |
| Food and Beverage | $30,465 | 663 | 7.5% |
| Honoraria | $28,007 | 8 | 6.9% |
| Travel and Lodging | $21,155 | 61 | 5.2% |
| Unspecified | $4,672 | 14 | 1.2% |
| Education | $486.69 | 8 | 0.1% |
Payments by Type
General
$400,520
851 transactions
Research
$4,672
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $75,434 | 103 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $74,880 | 82 | $0 (2024) |
| TG Therapeutics, Inc. | $60,226 | 42 | $0 (2024) |
| Biogen, Inc. | $50,603 | 64 | $0 (2024) |
| Horizon Therapeutics plc | $44,169 | 71 | $0 (2023) |
| Genentech USA, Inc. | $22,342 | 53 | $0 (2024) |
| GENZYME CORPORATION | $19,208 | 52 | $0 (2023) |
| Celgene Corporation | $16,123 | 65 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $14,998 | 97 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $10,969 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $151,570 | 167 | TG Therapeutics, Inc. ($59,450) |
| 2023 | $68,656 | 120 | EMD Serono, Inc. ($25,012) |
| 2022 | $112,263 | 243 | Biogen, Inc. ($30,521) |
| 2021 | $43,820 | 101 | GENZYME CORPORATION ($15,465) |
| 2020 | $10,096 | 33 | Alexion Pharmaceuticals, Inc. ($6,849) |
| 2019 | $8,151 | 92 | Celgene Corporation ($5,296) |
| 2018 | $10,094 | 95 | Celgene Corporation ($6,210) |
| 2017 | $541.59 | 14 | EMD Serono, Inc. ($128.14) |
All Payment Transactions
865 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Consulting Fee | Cash or cash equivalent | $6,255.00 | General |
| Category: Neurology | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $4.32 | General |
| Category: Neurology | ||||||
| 12/05/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $8.25 | General |
| Category: Neuroscience | ||||||
| 11/22/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $49.20 | General |
| 11/19/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,712.50 | General |
| Category: Immunology | ||||||
| 11/19/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $112.69 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $6.11 | General |
| Category: Neurology | ||||||
| 11/16/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $86.89 | General |
| 11/16/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $75.00 | General |
| 11/16/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $33.83 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Consulting Fee | Cash or cash equivalent | $4,820.00 | General |
| Category: Neurology | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Travel and Lodging | In-kind items and services | $588.54 | General |
| Category: Neurology | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $152.84 | General |
| Category: Neurology | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $49.35 | General |
| Category: Neurology | ||||||
| 11/14/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,712.50 | General |
| Category: Immunology | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $87.80 | General |
| Category: Neurology | ||||||
| 10/23/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,795.00 | General |
| Category: Neurology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: Neurology | ||||||
| 10/16/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $27.19 | General |
| Category: NEUROSCIENCE | ||||||
| 10/15/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $106.22 | General |
| Category: Immunology | ||||||
| 10/10/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,720.00 | General |
| Category: Rare Disease | ||||||
| 10/10/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | In-kind items and services | $827.52 | General |
| Category: Rare Disease | ||||||
| 10/10/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $102.21 | General |
| Category: Rare Disease | ||||||
| 10/04/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $29.47 | General |
| 10/04/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $2.37 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| HEOR | Novartis Pharmaceuticals Corporation | $2,711 | 1 |
| A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | SANOFI US SERVICES INC. | $1,961 | 13 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 189 | 382 | $154,711 | $47,454 |
| 2022 | 3 | 192 | 341 | $130,116 | $48,200 |
| 2021 | 3 | 342 | 487 | $189,832 | $74,345 |
| 2020 | 7 | 352 | 537 | $183,200 | $64,271 |
Total Patients
1,075
Total Services
1,747
Medicare Billing
$234,271
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 151 | 344 | $133,644 | $41,477 | 31.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 38 | 38 | $21,067 | $5,977 | 28.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 140 | 284 | $105,080 | $39,330 | 37.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 37 | 37 | $19,536 | $6,627 | 33.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 20 | $5,500 | $2,243 | 40.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 202 | 341 | $127,226 | $51,077 | 40.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 92 | 92 | $47,696 | $17,443 | 36.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 48 | 54 | $14,911 | $5,825 | 39.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 169 | 315 | $110,880 | $37,168 | 33.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 66 | 66 | $33,000 | $12,289 | 37.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 41 | 48 | $12,624 | $4,289 | 34.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 35 | 40 | $8,850 | $3,794 | 42.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 15 | 33 | $8,118 | $3,132 | 38.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 12 | $5,772 | $2,213 | 38.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 15 | 23 | $3,956 | $1,387 | 35.1% |
About Rahul Dave, M.D., PH.D
Rahul Dave, M.D., PH.D is a Neurology healthcare provider based in Fairfax, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/02/2010. The National Provider Identifier (NPI) number assigned to this provider is 1700101698.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Rahul Dave, M.D., PH.D has received a total of $405,192 in payments from pharmaceutical and medical device companies, with $151,570 received in 2024. These payments were reported across 865 transactions from 47 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($253,702).
As a Medicare-enrolled provider, Dave has provided services to 1,075 Medicare beneficiaries, totaling 1,747 services with total Medicare billing of $234,271. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology
- Location Fairfax, VA
- Active Since 04/02/2010
- Last Updated 04/21/2023
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1700101698
Products in Payments
- BRIUMVI (Drug) $60,226
- Mavenclad (Drug) $47,030
- UPLIZNA (Drug) $44,169
- ULTOMIRIS (Biological) $42,460
- VUMERITY (Drug) $40,594
- MAVENCLAD (Drug) $24,024
- AUBAGIO (Drug) $16,250
- OCREVUS (Biological) $15,068
- Soliris (Drug) $13,808
- KESIMPTA (Drug) $13,645
- ZEPOSIA (Drug) $11,160
- SOLIRIS (Biological) $8,122
- VYVGART (Drug) $7,266
- Ozanimod (Drug) $5,254
- Tysabri (Biological) $4,373
- Enspryng (Biological) $3,690
- Ocrevus (Biological) $3,660
- SYNCHROMED (Device) $1,646
- TYSABRI (Biological) $1,380
- MAYZENT (Drug) $664.45
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Fairfax
John Rothrock, Md, MD
Neurology — Payments: $347,072
Neurology $347,072
Laura Cinski, M.d, M.D
Neurology — Payments: $70,544
Neurology $70,544
Abigail Lawler, M.d, M.D
Neurology — Payments: $45,925
Neurology $45,925
Dr. David Whitney, M.d, M.D
Neurology — Payments: $35,830
Neurology $35,830
Dr. Amy Safadi, Md, MD
Neurology — Payments: $22,090
Neurology $22,090
Hannah Irving, Md, MD
Neurology — Payments: $6,570
Neurology $6,570